Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function

Casey Wright, Colin S. Duckett

Research output: Contribution to journalReview article

94 Citations (Scopus)

Abstract

Recent studies have shown that members of the inhibitor of apoptosis (IAP) protein family are highly expressed in several classes of cancer. The primary implication of these findings is that the elevated expression of IAPs is not coincidental but actually participates in oncogenesis by helping to allow the malignant cell to avoid apoptoric cell death. TMs concept, together with the discovery of several IAP-regulatory proteins that use a conserved mode of action, has stimulated a major effort by many research gronaps to devise IAP-targering strategies as a means of developing novel antineoplastic drugs. In this Review, we consider the evidence both for and against the IAPs being valid therapeutic targets, and we describe the types of strategies being used to neutralize their functions.

Original languageEnglish (US)
Pages (from-to)2673-2678
Number of pages6
JournalJournal of Clinical Investigation
Volume115
Issue number10
DOIs
StatePublished - Oct 2005
Externally publishedYes

Fingerprint

Inhibitor of Apoptosis Proteins
Apoptosis
Apoptosis Regulatory Proteins
Antineoplastic Agents
Neoplasms
Carcinogenesis
Cell Death
Therapeutics
Research

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. / Wright, Casey; Duckett, Colin S.

In: Journal of Clinical Investigation, Vol. 115, No. 10, 10.2005, p. 2673-2678.

Research output: Contribution to journalReview article

@article{453137201cd245a5bffbdc27337e4098,
title = "Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function",
abstract = "Recent studies have shown that members of the inhibitor of apoptosis (IAP) protein family are highly expressed in several classes of cancer. The primary implication of these findings is that the elevated expression of IAPs is not coincidental but actually participates in oncogenesis by helping to allow the malignant cell to avoid apoptoric cell death. TMs concept, together with the discovery of several IAP-regulatory proteins that use a conserved mode of action, has stimulated a major effort by many research gronaps to devise IAP-targering strategies as a means of developing novel antineoplastic drugs. In this Review, we consider the evidence both for and against the IAPs being valid therapeutic targets, and we describe the types of strategies being used to neutralize their functions.",
author = "Casey Wright and Duckett, {Colin S.}",
year = "2005",
month = "10",
doi = "10.1172/JCI26251",
language = "English (US)",
volume = "115",
pages = "2673--2678",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "10",

}

TY - JOUR

T1 - Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function

AU - Wright, Casey

AU - Duckett, Colin S.

PY - 2005/10

Y1 - 2005/10

N2 - Recent studies have shown that members of the inhibitor of apoptosis (IAP) protein family are highly expressed in several classes of cancer. The primary implication of these findings is that the elevated expression of IAPs is not coincidental but actually participates in oncogenesis by helping to allow the malignant cell to avoid apoptoric cell death. TMs concept, together with the discovery of several IAP-regulatory proteins that use a conserved mode of action, has stimulated a major effort by many research gronaps to devise IAP-targering strategies as a means of developing novel antineoplastic drugs. In this Review, we consider the evidence both for and against the IAPs being valid therapeutic targets, and we describe the types of strategies being used to neutralize their functions.

AB - Recent studies have shown that members of the inhibitor of apoptosis (IAP) protein family are highly expressed in several classes of cancer. The primary implication of these findings is that the elevated expression of IAPs is not coincidental but actually participates in oncogenesis by helping to allow the malignant cell to avoid apoptoric cell death. TMs concept, together with the discovery of several IAP-regulatory proteins that use a conserved mode of action, has stimulated a major effort by many research gronaps to devise IAP-targering strategies as a means of developing novel antineoplastic drugs. In this Review, we consider the evidence both for and against the IAPs being valid therapeutic targets, and we describe the types of strategies being used to neutralize their functions.

UR - http://www.scopus.com/inward/record.url?scp=26444470888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26444470888&partnerID=8YFLogxK

U2 - 10.1172/JCI26251

DO - 10.1172/JCI26251

M3 - Review article

VL - 115

SP - 2673

EP - 2678

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 10

ER -